Mechanisms of resistance to antiangiogenic therapies.
Therapeutic studies in Kidney Cancer murine models, both PDOX and syngenic.
Therapeutic studies in pancreatic NeuroEndocrine tumors.
Discovery of non-invasive biomarkers in clinical trials with antiangiogenics.
Our research group at the ProCURE Program (Catalan Institute of Oncology) and OncoBell Program (IDIBELL) is focused on determining the consequences of adaptation and resistance to anti-angiogenic cancer therapy. For that we use translational research in murine models of cancer, particularly Kindey Cancer PDOX models and NeuroEndocrine transgenic models to study in vivo mechanisms of adaptation to anti-angiogenics, and validate our findings using clinical samples from our hospital and collaborating institutions.
Our scientific achievements have been published in prestigious journals in the field of cancer research with numerous “preview”, “highlight” or commentary articles in high impact scientific journals. Furthermore, we have an important international position in the field of antitumor therapies and angiogenic resistance mechanisms.
Group members
Publications
Mol Cell Oncol. 2016 Jul 14;3(5):e1211979. doi: 10.1080/23723556.2016.1211979. eCollection 2016. ABSTRACT Several types of tumor are currently treated with antiangiogenic drugs. Unfortunately, most of these patients develop therapy resistance and succumb to the disease. Recently, a novel mechanism of resistance to antiangiogenics involving metabolic symbiosis of tumor cells has been described. Strategies to block resistance […]
Target Oncol. 2017 Feb;12(1):19-35. doi: 10.1007/s11523-016-0463-4. ABSTRACT Renal cell carcinoma (RCC) is a complex disease characterized by mutations in several genes. Loss of function of the von Hippel-Lindau (VHL) tumour suppressor gene is a very common finding in RCC and leads to up-regulation of hypoxia-inducible factor (HIF)-responsive genes accountable for angiogenesis and cell growth, such […]
Oncogene. 2017 Apr 6;36(14):1899-1907. doi: 10.1038/onc.2016.316. Epub 2016 Sep 19. ABSTRACT Interest in research on neuroendocrine tumors (NETs) has grown in the past 10 years, coinciding with improvements in our understanding of the molecular pathogenesis of NETs. In addition, NETs have become one of the most exciting settings for drug development. Two targeted agents for […]
Oncotarget. 2016 Sep 13;7(37):60110-60122. doi: 10.18632/oncotarget.11076. ABSTRACT The truncated somatostatin receptor sst5TMD4 is associated with poor prognosis in breast cancer and increases breast cancer cell malignancy. Here, we examined the cellular/molecular mechanisms underlying this association, aiming to identify new molecular tools to improve diagnosis, prognosis or therapy. A gene expression array comparing sst5TMD4 stably-transfected MCF-7 […]
Int J Cancer. 2016 Oct 15;139(8):1894-903. doi: 10.1002/ijc.30233. Epub 2016 Jun 25. ABSTRACT In a search for new therapeutic targets for treating epithelial ovarian cancer, we analyzed the Transforming Growth Factor Beta (TGFβ) signaling pathway in these tumors. Using a TMA with patient samples we found high Smad2 phosphorylation in ovarian cancer tumoral cells, independently […]
Research Projects
Collaborations
International:
Douglas Hanahan, ISREC
Gabriele Bergers, KULeuven
Masahiro Inoue, Univ.Osaka
Kristian Pietras, Karolinska I.
Enrico Giraudo, IRCC
Stefano Indraccolo, IOV
National:
Joan Carles, VHIO
Cristina Suárez, VHIO
Maria Ochoa, ICO
August Vidal, HUB
Ramon Salazar, ICO
X García del Muro, ICO
Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952
Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069
Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087
Viñals’s lab